Citation Impact
Citing Papers
Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase
2005 StandoutNobel
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
2007 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Demethylation of 3-Methylthymine in DNA by Bacterial and Human DNA Dioxygenases
2004 StandoutNobel
Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions
2002
The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling
2000
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
2007
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents
2000 Standout
Glioblastoma and Other Malignant Gliomas
2013 Standout
Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O6-alkylguanine-DNA alkyltransferase
2000
The type III epidermal growth factor receptor mutation
2001
Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas
2017
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
2009
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Recent progress on the Ada response for inducible repair of DNA alkylation damage
2002 StandoutNobel
Biodegradable polymer implants to treat brain tumors
2001
MGMT: its role in cancer aetiology and cancer therapeutics
2004
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group
2005 StandoutNobel
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Cancer nanotechnology: opportunities and challenges
2005 Standout
Epigenetics in Cancer
2008 Standout
Minimal Methylated Substrate and Extended Substrate Range of Escherichia coli AlkB Protein, a 1-Methyladenine-DNA Dioxygenase
2003 StandoutNobel
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Targeted Molecular Therapy of GBM
2003
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
2007
Malignant Gliomas in Adults
2008 Standout
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity
2003
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme
2006
EGF mutant receptor vIII as a molecular target in cancer therapy.
2001
Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine
2010 StandoutNobel
Progress and problems in the application of focused ultrasound for blood–brain barrier disruption
2008
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
DNA repair dysregulation from cancer driver to therapeutic target
2012
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Primary brain tumours in adults
2012 Standout
Ligand-targeted therapeutics in anticancer therapy
2002
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
2001
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
2003 Standout
A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
2008
Tumour vascular targeting
2005
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Gold Nanorods: From Synthesis and Properties to Biological and Biomedical Applications
2009 Standout
Repair of O6-alkylguanine by alkyltransferases
2000
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach
2000
Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme
2002
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Brain Tumors
2001 Standout
Renal clearance of quantum dots
2007 StandoutNobel
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
2008 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
2001
Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
2002
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results
2005
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
2002 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
2005 Standout
De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor
2019 StandoutNobel
Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy
2003
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Human DNA Repair Genes
2001 StandoutScienceNobel
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
2002
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]
2000
Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme
2002
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
2004 StandoutNobel
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway
2003
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
2000
Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
2000
Works of Ilkcan Cokgor being referenced
Monoclonal Antibody Therapy of Human Gliomas: Current Status and Future Approaches
1999
Dosimetry and dose–response relationships in newly diagnosed patients with malignant gliomas treated with Iodine-131-Labeled anti-tenascin monoclonal antibody 81C6 therapy
2000
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
1998
Phase I study of Gliadel™ wafers plus temozolomide in adults withrecurrent supratentorial high-grade gliomas
2001
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
1998
Chemotherapy for Adults with Malignant Glioma
1999
Topotecan treatment of adults with primary malignant glioma
1999
Topotecan treatment of adults with primary malignant glioma
1999
Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas
2000
Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
2002
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
1999